{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
icosapent ethyl
to a specific field?
Class (Stereo):
CHEMICAL (ACHIRAL)
Pheneridine is a synthetic opioid. It was developed as a narcotic agent.
Status:
Investigational
Source:
NCT04638803: Early Phase 1 Interventional Completed Healthy Volunteers
(2021)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT03756103: Phase 2 Interventional Completed Hypertension,Essential
(2019)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT04323124: Phase 1 Interventional Terminated Healthy
(2020)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Class (Stereo):
CHEMICAL (RACEMIC)
Pifenate is an analgesic agent.
Status:
Investigational
Source:
NCT04461119: Phase 2 Interventional Completed Schizophrenia
(2020)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Evenamide (NW-3509) is a blocker of voltage-gated sodium channels. Evenamide modulates sustained repetitive firing, without inducing impairment of normal neuronal excitability. It normalizes glutamate release induced by aberrant sodium channel activity. The potential benefits of the compound have been demonstrated in numerous preclinical models predictive of efficacy in psychiatric diseases, including models of psychosis such as amphetamine-induced hyperactivity, sensorimotor gating and information processing deficits (pre-pulse inhibition impairment induced by different stimuli), mania and depression. Evenamide is being evaluated in a Phase II trial as add-on treatment to 5HT2/D2 blocking antipsychotics in schizophrenic patients.
Status:
Investigational
Source:
NCT02753699: Phase 3 Interventional Completed Hepatitis C
(2011)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Alisporivir (DEBIO-025) is a first-in-class synthetic cyclophilin inhibitor, in development with Debiopharm as an oral treatment for hepatitis C virus (HCV) infections. Alisporivir has the potential to be used for the treatment of additional diseases such as other viral infections, certain muscular dystrophies, and myocardial infarction. Alisporivir has potent anti-hepatitis C virus (HCV) activity both in vitro and in vivo. It is currently being evaluated in phase II clinical trials.
Class (Stereo):
CHEMICAL (ACHIRAL)
Betoxycaine was used as a local anesthetic.
Status:
Investigational
Source:
INN:imiclopazine [INN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Imiclopazine is a phenothiazines derivative patented by Asta-Werke A.-G. as strong sedative and antiemetic agent. Imiclopazine was studied for treatment of schizophrenia but was never marketed.
Status:
Investigational
Source:
NCT00385307: Phase 3 Interventional Completed Major Depressive Disorder
(2006)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Amibegron (SR 58611A or SR 58611) is a highly selective agonist for atypical beta3-adrenoceptors. It stimulates neuronal activity in a specific area of the prefrontal cortex and also inhibits intestinal motility. Amibegron was in phase III trials worldwide for the treatment of depression and generalised anxiety disorder but development of the product was discontinued in 2008. Amibegron has been tested for its potential as a treatment for irritable bowel syndrome.
